[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anal-carcinoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100490236","collecting-blood-and-tissue-sample-donations-for-research-for-hivaids-related-cancers-100490236",false,"NCT05663502","Collecting Blood and Tissue Sample Donations for Research for HIV\u002FAIDS-Related Cancers","Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials","Inclusion Criteria:\n\n* Participants must be at least 18 years of age\n* Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as:\n\n  * classic Kaposi sarcoma\n  * transplant-associated Kaposi sarcoma,\n  * anal cancer,\n  * multicentric Castleman's disease,\n  * Epstein Barr Virus (EBV) -positive lymphoma\n  * plasmablastic lymphoma\n  * Hodgkin's lymphoma.\n\n    * For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: :\n\n      * Documentation of HIV diagnosis in the medical record by a licensed health care provider;\n      * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \\[e.g., Truvada\\], which is exclusionary);\n      * HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \\> 1000 RNA copies\u002FmL;\n      * Any licensed HIV screening antibody and\u002For HIV antibody\u002Fantigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay.\n* Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer.\n* The investigator determines that the participant (or his\u002Fher legally authorized representative \\[LAR\\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)\u002Facquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.",[24,25,26,27,28,29,30,31,32,33,34,35],"Anal Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","HIV Infection","Kaposi Sarcoma","Lymphoma","Malignant Solid Neoplasm","Multicentric Castleman Disease","Plasmablastic Lymphoma","Recurrent Kaposi Sarcoma","Recurrent Lymphoma","Recurrent Plasmablastic Lymphoma","Transplant-Related Kaposi Sarcoma","RECRUITING","2026-05-28",{"date":39,"type":40},"2026-06-01","ACTUAL",{"date":42,"type":40},"2023-05-10",{"date":44,"type":20},"2035-08-31",{"name":46,"class":47},"AIDS Malignancy Consortium","NETWORK",8,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100624285","phase-2-vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer-100624285","NCT07407647","Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer","Vaginal DHEA for Women With Gynecologic and Gastrointestinal Cancer After Radiation","Inclusion Criteria:\n\n* Any patient with anal, rectal, cervical, vaginal, or vulvar cancer receiving external beam radiation alone, or both external beam radiation and brachytherapy with curative intent (Participants will be consented and enrolled prior to starting treatment but will not receive intervention till after treatment is completed)\n* Concurrent or prior chemotherapy is allowed\n* Any prior gynecologic surgery is permitted\n* Rectal surgery, including lower anterior resection and abdominoperineal resection, is permitted\n* Subject must be menopausal, which is defined as age \\> 50 with no menses for 12 months or bilateral oophorectomy\n\nExclusion Criteria:\n\n* Patients with scleroderma, mixed connective tissue disorder, and lupus will be excluded\n* Patients who have received prior pelvic radiation\n* Undiagnosed abnormal genital bleeding (unrelated to current diagnosis or treatment related toxicity)\n* Endometrial cancer or endometrial hyperplasia\n* Use of estrogen alone injectable or progestin implant therapy with 3 months before study entry\n* Use of estrogen pellet or progestin injectable drug within 6 months before study entry\n* Use of oral estrogen, progestin, or DHEA or intrauterine progestin within 8 weeks before study entry\n* Use of vaginal estrogen (rings, creams, tablets, or gels), transdermal estrogen +\u002F- progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments such as black cohosh in the 4 weeks before study entry. Intravaginal moisturizers and lubricants prior to enrollment are permitted\n* History of breast cancer\n* Patients receiving palliative radiation therapy\n* Patients who do not meet criteria for menopause","FEMALE","50 Years",{"count":59,"type":20},25,"INTERVENTIONAL",[62],"PHASE2","This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.",[24,65,66,67,68,69],"Cervical Carcinoma","Malignant Female Reproductive System Neoplasm","Rectal Carcinoma","Vaginal Carcinoma","Vulvar Carcinoma","2026-04-16",{"date":72,"type":40},"2026-04-21",{"date":74,"type":40},"2026-03-12",{"date":76,"type":20},"2026-12-31",{"name":78,"class":79},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":80},"100472972","re-optimization-based-online-adaptive-radiotherapy-of-anal-cancer-100472972","NCT05438836","Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","ROAR-A","Inclusion Criteria:\n\n* Biopsy-verified anal cancer\n* Eligible for curative intended radiotherapy\n* Written and oral consent\n\nExclusion Criteria:\n\n* Other malignant disease within the past 5 years (excluding basal cell carcinoma)",{"count":90,"type":20},205,"A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).",[93,24,94],"Anal Cancer","Anal Squamous Cell Carcinoma",[96,97,98],"adaptive radiotherapy","Anal cancer","Online Adaptive radiotherapy (oART)","2023-09-21",{"date":101,"type":40},"2023-09-25",{"date":103,"type":40},"2022-01-01",{"date":105,"type":20},"2031-01-01",{"name":107,"class":79},"Herlev Hospital"]